NPO Earnings

NPO reported its earnings on 2026-02-18, showcasing a revenue of 295.40M against an estimate of 280.50M, resulting in a 5.31% surprise. The EPS was 1.99, surpassing the expected 1.91 by 4.19%. The stock experienced a 0.7% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NPO's earnings announcement on 2026-02-18, the stock price moved by 0.7% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NPO's stock price tends to shift by an average of -0.71% in the 10 days leading up to earnings and 2.54% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NPO's annual revenue to reach 280.50M, while the EPS is projected at 1.91. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised upward by 2.17% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NPO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised upward by 2.17%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NPO's stock price typically moves by -0.71% in the 10 days before its earnings and 2.54% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.91 and revenue of 280.50M.

The earnings call presents strong financial performance with significant year-over-year growth in revenue, EBITDA, and EPS. The company has raised its guidance for revenue and EBITDA, indicating optimism. The Q&A section reveals positive momentum in AST and Sealing Technologies, despite some uncertainty in nuclear choppiness. The market cap suggests moderate volatility, but overall, the positive financial metrics and improved guidance outweigh any concerns, leading to a positive outlook.